LEADER 03962nam 2200649 a 450 001 9910824723903321 005 20200520144314.0 010 $a1-281-23718-3 010 $a9786611237189 010 $a0-470-17011-5 010 $a0-470-17010-7 035 $a(CKB)1000000000407914 035 $a(EBL)333734 035 $a(OCoLC)476138229 035 $a(SSID)ssj0000117350 035 $a(PQKBManifestationID)11128208 035 $a(PQKBTitleCode)TC0000117350 035 $a(PQKBWorkID)10048946 035 $a(PQKB)10416506 035 $a(MiAaPQ)EBC333734 035 $a(Au-PeEL)EBL333734 035 $a(CaPaEBR)ebr10226803 035 $a(CaONFJC)MIL123718 035 $a(PPN)199222746 035 $a(EXLCZ)991000000000407914 100 $a20070209d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCancer vaccines and tumor immunity /$f[edited by] Rimas Orentas, James W. Hodge, Bryon D. Johnson 205 $a1st ed. 210 $aHoboken, N.J. $cWiley-Interscience$dc2008 215 $a1 online resource (352 p.) 300 $aDescription based upon print version of record. 311 $a0-470-07474-4 320 $aIncludes bibliographical references and index. 327 $aCANCER VACCINES AND TUMOR IMMUNITY; CONTENTS; Contributors; Foreword CANCER VACCINES AND CANCER IMMUNOTHERAPY: A NEW PARADIGM; I INTRODUCTION; 1 CANCER VACCINES: PROGRESS AND PROMISE; II ADJUVANT THERAPY: ENHANCING THE ENDOGENOUS IMMUNE RESPONSE; 2 FULLY SYNTHETIC CARBOYHYDRATE-BASED ANTITUMOR VACCINES; 3 BACILLUS CALMETTE-GUE?RIN IMMUNOTHERAPY OF GENITOURINARY CANCER; 4 STIMULATION OF TOLL-LIKE RECEPTOR 9 FOR ENHANCING VACCINATION; III ANTIGEN-SPECIFIC THERAPY: NOVEL PRESENTATION OF PEPTIDE AND PROTEIN ANTIGENS; 5 POLYEPITOPE VACCINES 327 $a6 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPY: HPV-ASSOCIATED CERVICAL CANCER AS A MODEL SYSTEM7 POXVIRAL VECTORS FOR CANCER VACCINES: STATE OF THE ART; 8 IMMUNOTHERAPEUTIC STRATEGIES AGAINST CANCER USING Listeria monocytogenes AS A VECTOR FOR TUMOR ANTIGENS; 9 COUPLING INNATE AND ADAPTIVE IMMUNITY WITH YEAST-BASED CANCER IMMUNOTHERAPY; IV CELL-BASED THERAPY: USING CANCER CELLS AS A MEANS TO INDUCE SPECIFIC TUMOR IMMUNITY; 10 ALLOGENEIC WHOLE-CELL VACCINES; 11 JUMP-STARTING TUMOR IMMUNITY WITH BREAST CANCER THERAPEUTICS; 12 T-REGULATORY CELL MANIPULATION IN TUMOR IMMUNOTHERAPY 327 $a13 TUMOR VACCINATION AFTER AUTOLOGOUS HSCT: WHAT HAS BEEN LEARNED FROM EXPERIMENTAL MODELS14 VACCINES IN THE SETTING OF HEMATOPOIETIC STEM CELL TRANSPLANTATION; 15 INTRATUMOR GENERATION OF VIGOROUS ANTITUMOR IMMUNE RESPONSES; 16 CANCER IMMUNOTHERAPY: UNTAPPING THE POTENTIAL OF COSTIMULATORY MOLECULES BEYOND CTLA-4; V DEFINING EFFECTIVE CLINICAL RESPONSES; 17 ADVANCES IN IMMUNE MONITORING STRATEGIES FOR CANCER VACCINES AND IMMUNOTHERAPY; 18 IMMUNE EVALUATION OF CANCER VACCINES; Index 330 $aCancer Vaccines and Tumor Immunity offers a review of the basic scientific discoveries that have moved forward into clinical trials. Presented in the context of real-world human research and experimentation, these major scientific advances demonstrate how our understanding of immune activation, T-regulatory cells, and autoimmunity will impact cancer vaccine design. The authors also explain how vaccination in the context of bone marrow transplantation will open new avenues for clinical study in the future. 606 $aCancer vaccines 606 $aTumors$xImmunological aspects 615 0$aCancer vaccines. 615 0$aTumors$xImmunological aspects. 676 $a616.99/407 701 $aOrentas$b Rimas$01648337 701 $aHodge$b James W$01648338 701 $aJohnson$b Bryon D$01648339 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910824723903321 996 $aCancer vaccines and tumor immunity$93996402 997 $aUNINA